Emília Sousa de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emília Sousa de Oliveira has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Abel Botelho Quaresma
Health Sciences Postgraduate Program, IBD outpatient clinics, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil; Universidade do Oeste de Santa Catarina, UNOESC, Joaçaba, Brazil
1 shared publication - Alessandra Lima da Silva
Universidade Federal de Minas Gerais, Brazil
1 shared publication - Aline Sampaio Cremonesi
Universidade São Francisco
1 shared publication Aline de Paula Dias da Silva
1 shared publication- Ana Carolina Silva Bulla
Programa de Pós-Graduação em Biologia Computacional e Sistemas, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ 21040-900, Brazil
1 shared publication - Ana Paula de Abreu
Laboratory of Bioinformatics and Systems, Department of Computer Science, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil
1 shared publication
Latest Publications
- Open Access
- 30 December 2024
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otae082
Temporal Trends in Surgery and Hospitalization Rates for Crohn’s Disease in Brazil: A Population-Based Study
Introduction: Biological therapy has transformed the natural course of inflammatory bowel disease, but there are still controversies regarding its potential to reduce surgical rates for Crohn’s disease (CD). This study, conducted with the support of the Brazilian National Healthcare System, aimed to analyze temporal trends in surgery and hospitalization rates among patients with CD and to correlate these data with the dispensing of azathioprine (AZA), infliximab (IFX), and adalimumab (ADA). Methodology: This retrospective observational study used data from the National Public Healthcare Department of Informatics through the TT Disease Explorer® platform from 2012 to 2022. Demographic data, medications used, and the prevalence of surgical procedures and hospitalizations associated with the International Classification of Diseases codes for CD were analyzed. Annual average percent changes (AAPCs) were calculated to assess temporal trends. Results: Between 2012 and 2022, there was a significant increase of 288.07% in the diagnoses of CD, rising from 27 551 to 106 917 cases. Concurrently, there was an increase in the absolute number of patients treated with AZA, IFX, and ADA, with increasing rates of 65.79%, 251.09%, and 242.48%, respectively. However, the proportion of patients receiving AZA per CD patients decreased by 57.28%, from 44.79% to 19.13% (AAPC = −7.94%, 95% CI, −8.05 to −7.83; P < .001). The use of IFX remained relatively stable, with a slight change from 13.82% to 12.50% (AAPC = 0.01%, 95% CI, −0.20 to 0.22; P = .935), while the use of ADA decreased by 11.75%, from 11.65% to 10.28% (AAPC = −1.74%, 95% CI, −2.48 to −1.82; P < .001). The absolute number of hospitalizations related to CD increased by 57.71%. Despite the rise in the number of cases and the greater availability of biological treatments, the proportion of hospitalized patients decreased by 59.29%, from 6.19% to 2.52% (AAPC = −7.04%, 95% CI, −7.42 to −6.66; P < .001). Similarly, the proportion of surgical procedures relative to the total number of cases decreased by 55.08%, from 1.09% to 0.49% (AAPC = −5.73%, 95% CI, −6.68 to −4.77; P < .001). Conclusions: Despite the cumulative increase in the prevalence of CD cases in the country and the absolute increase in the dispensing of biologics, the proportion of hospitalizations and surgical procedures among CD patients treated in the public health system in Brazil decreased.
- 30 December 2024
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (1) , otae082
Open AccessTemporal Trends in Surgery and Hospitalization Rates for Crohn’s Disease in Brazil: A Population-Based Study
Introduction: Biological therapy has transformed the natural course of inflammatory bowel disease, but there are still controversies regarding its potential to reduce surgical rates for Crohn’s disease (CD). This study, conducted with the support of the Brazilian National Healthcare System, aimed to analyze temporal trends in surgery and hospitalization rates among patients with CD and to correlate these data with the dispensing of azathioprine (AZA), infliximab (IFX), and adalimumab (ADA). Methodology: This retrospective observational study used data from the National Public Healthcare Department of Informatics through the TT Disease Explorer® platform from 2012 to 2022. Demographic data, medications used, and the prevalence of surgical procedures and hospitalizations associated with the International Classification of Diseases codes for CD were analyzed. Annual average percent changes (AAPCs) were calculated to assess temporal trends. Results: Between 2012 and 2022, there was a significant increase of 288.07% in the diagnoses of CD, rising from 27 551 to 106 917 cases. Concurrently, there was an increase in the absolute number of patients treated with AZA, IFX, and ADA, with increasing rates of 65.79%, 251.09%, and 242.48%, respectively. However, the proportion of patients receiving AZA per CD patients decreased by 57.28%, from 44.79% to 19.13% (AAPC = −7.94%, 95% CI, −8.05 to −7.83; P < .001). The use of IFX remained relatively stable, with a slight change from 13.82% to 12.50% (AAPC = 0.01%, 95% CI, −0.20 to 0.22; P = .935), while the use of ADA decreased by 11.75%, from 11.65% to 10.28% (AAPC = −1.74%, 95% CI, −2.48 to −1.82; P < .001). The absolute number of hospitalizations related to CD increased by 57.71%. Despite the rise in the number of cases and the greater availability of biological treatments, the proportion of hospitalized patients decreased by 59.29%, from 6.19% to 2.52% (AAPC = −7.04%, 95% CI, −7.42 to −6.66; P < .001). Similarly, the proportion of surgical procedures relative to the total number of cases decreased by 55.08%, from 1.09% to 0.49% (AAPC = −5.73%, 95% CI, −6.68 to −4.77; P < .001). Conclusions: Despite the cumulative increase in the prevalence of CD cases in the country and the absolute increase in the dispensing of biologics, the proportion of hospitalizations and surgical procedures among CD patients treated in the public health system in Brazil decreased.
- 1 September 2023
- Published by ALFAHELIX
BIOINFO #03 - Revista Brasileira de Bioinformática e Biologia Computacional
A Revista BIOINFO é a primeira revista brasileira voltada a publicação de trabalhos de divulgação científica em bioinformática e biologia computacional, publicada em língua portuguesa e voltada ao público universitário. De setembro de 2022 a setembro de 2023, a revista recebeu mais de 24 mil visitantes únicos. No mesmo período entre os anos de 2021 e 2022, o número de visitantes foi um pouco superior a 17 mil, o que indica um aumento de mais de 40% no total de acessos. Todos esses fatores destacam a importância que a revista adquiriu recentemente. Nesta terceira edição, 26 artigos foram aceitos para a publicação. Os artigos foram publicados em 12 principais categorias. A categoria com maior número de submissões foi Bioinformática Estrutural (8), seguido por Virologia (4), Tutoriais (4), Genômica (4), Evolução (2), Ensino (2), Sequenciamento (1), Transcriptômica (1), Biologia de sistemas (1), Bioquímica (1), Bancos de dados (1) e Computação (1). Boa leitura!
- 1 September 2023
- Published by ALFAHELIX
BIOINFO #03 - Revista Brasileira de Bioinformática e Biologia Computacional
A Revista BIOINFO é a primeira revista brasileira voltada a publicação de trabalhos de divulgação científica em bioinformática e biologia computacional, publicada em língua portuguesa e voltada ao público universitário. De setembro de 2022 a setembro de 2023, a revista recebeu mais de 24 mil visitantes únicos. No mesmo período entre os anos de 2021 e 2022, o número de visitantes foi um pouco superior a 17 mil, o que indica um aumento de mais de 40% no total de acessos. Todos esses fatores destacam a importância que a revista adquiriu recentemente. Nesta terceira edição, 26 artigos foram aceitos para a publicação. Os artigos foram publicados em 12 principais categorias. A categoria com maior número de submissões foi Bioinformática Estrutural (8), seguido por Virologia (4), Tutoriais (4), Genômica (4), Evolução (2), Ensino (2), Sequenciamento (1), Transcriptômica (1), Biologia de sistemas (1), Bioquímica (1), Bancos de dados (1) e Computação (1). Boa leitura!
- Open Access
- 1 July 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (9)
Co-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil
Acinetobacter baumannii is a common and dangerous non-fermenting gram-negative bacillus due to its various and increasing resistance mechanisms. Therefore, the objective of the work was to describe four NDM-1 -producing Acinetobacter isolates from Natal, northeastern Brazil. These four isolates were identified as Acinetobacter baumannii by MALDI-TOF. All isolates were characterized by antimicrobial susceptibility testing, with resistance to all β-lactams including carbapenems and positive for the synergy test with Ethylenediaminetetraacetic acid. PCR analysis was also performed for blaNDM-1, blaVIM-1, blaIMP-1, blaOXA-23, blaOXA-24/40, blaOXA-51, blaOXA-58, and blaOXA-143 genes and showed positive for the blaNDM-1 and blaOXA-23 genes in all isolates and this result was confirmed by sequencing. This is the first case of Acinetobacter baumannii strains harboring blaNDM-1 gene isolated from northeastern Brazil. This description emphasizes the need for new prevention and control strategies of the dissemination of NDM-1-producing Acinetobacter, which are associated with a high mortality rate.
- 1 July 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (9)
Open AccessCo-production of blaNDM-1 and blaOXA-23 in multiresistant clinical isolates of Acinetobacter baumannii from Brazil
Acinetobacter baumannii is a common and dangerous non-fermenting gram-negative bacillus due to its various and increasing resistance mechanisms. Therefore, the objective of the work was to describe four NDM-1 -producing Acinetobacter isolates from Natal, northeastern Brazil. These four isolates were identified as Acinetobacter baumannii by MALDI-TOF. All isolates were characterized by antimicrobial susceptibility testing, with resistance to all β-lactams including carbapenems and positive for the synergy test with Ethylenediaminetetraacetic acid. PCR analysis was also performed for blaNDM-1, blaVIM-1, blaIMP-1, blaOXA-23, blaOXA-24/40, blaOXA-51, blaOXA-58, and blaOXA-143 genes and showed positive for the blaNDM-1 and blaOXA-23 genes in all isolates and this result was confirmed by sequencing. This is the first case of Acinetobacter baumannii strains harboring blaNDM-1 gene isolated from northeastern Brazil. This description emphasizes the need for new prevention and control strategies of the dissemination of NDM-1-producing Acinetobacter, which are associated with a high mortality rate.